Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naive HIV-1 Infected Patients.

Trial Profile

Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naive HIV-1 Infected Patients.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Raltegravir (Primary) ; Maraviroc
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2012 Planned End Date changed from 1 Sep 2012 to 1 Sep 2014 according to ClinicalTrials.gov record.
    • 25 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top